SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-323947
Filing Date
2020-12-22
Accepted
2020-12-22 08:49:58
Documents
2
Group Members
TYTO ACQUISITION CORP

Document Format Files

Seq Description Document Type Size
1 SC 13D d56823dsc13d.htm SC 13D 88732
2 EX-99.1 d56823dex991.htm EX-99.1 3064
  Complete submission text file 0001193125-20-323947.txt   93520
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Filed by) CIK: 0000059478 (see all company filings)

IRS No.: 350470950 | State of Incorp.: IN | Fiscal Year End: 1231
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations

Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Subject) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91049 | Film No.: 201406179
SIC: 2836 Biological Products, (No Diagnostic Substances)